The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer

Матвеев, В. Б.; Киричек, А. А.; Сафронова, В. М.; Kokosadze, N V; Khalmurzaev, Oybek; Камолов, Б. Ш.; Любченко, Л. Н.

doi:10.17650/1726-9776-2019-15-1-57-65

Cited by 8 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a smaller series (n = 45), the median MFS was shorter in PD-L1+ patients (49 vs. 68 months; p = 0.090): multivariate analysis confirmed the independent predictive value of expression and hyperexpression of PD-L1 in tumor cells for MFS (p = 0.025, p = 0.032) and CSS (p = 0.097, p = 0.065) [38].…”

mentioning

confidence: 69%

“…The positivity rate of PD-L1 seemed higher in CRPCs (440/904, 49%) [8,9,13,17,21,27,35,38,50,55,59,62,66,74,90,92,[98][99][100] as compared to hormone-sensitive PCs (44/254, 17%): PD-L1 was usually tested on primary tumors that probably had not yet undergone hormonal therapy as this information was not always available [27,32,35,39].…”

Section: Pd-l1 Expression and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Palicelli

Bonacini

Croci

et al. 2021

Cells

View full text Add to dashboard Cite

Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.

show abstract

mentioning

confidence: 69%

Section: Pd-l1 Expression and Treatmentmentioning

confidence: 99%

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Palicelli

Bonacini

Croci

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…We found that 29% of acinar PCs, 7% of ductal PCs, and 46% of neuroendocrine carcinomas or tumors were classified as PD-L1-positive by immunohistochemical analysis on tumor tissue, despite these results may be influenced by some selection biases [8,9,[11][12][13]17,21,27,29,32,[35][36][37][38][39][41][42][43][44][50][51][52][53][54][55]57,[59][60][61][62]66,67,74,75,[77][78][79][83][84][85]89,90,[92][93][94][98][99][100]111,…”

Section: Discussionmentioning

confidence: 99%

“…1369/4708 (29%) PCs were overall classified as positive but different antibody clones, scoring systems, and/or cut-offs for positivity were used, with a range as wide as 0-100% in single studies. 687/2676 (26%) cases were considered PD-L1-positive if at least ≥1% of tumor cells were stained [8,13,27,29,[35][36][37][38][39][41][42][43]54,62,66,67,74,75,[77][78][79]84], while 93/1062 (9%) PCs were counted as positive for ≥5% of stained tumor cells [17,39,43,57,66,94,[98][99][100]120]. 9/523 (2%) cases expressed PD-L1 on >50% of tumor cells [66,92], while Wang et al used a cut-off of ≥25% (0/21, 0%) [61].…”

Section: Pd-l1 Immunohistochemical Expression In Prostate Cancermentioning

confidence: 99%

“…When data were available and analyzable, the PD-L1 positivity rate of non-TMA specimens was 50% (240/483) for biopsies [9,11,12,21,32,62,90] and 41% (587/1427) for RPs [18,38,[42][43][44]57,61,75,79,94]. In TMA series (variably including RPs, biopsies, TURPs, metastases, autopsies), the expression rate was lower (258/1728, 15%) [27,29,35,39,41,53,66,67,74,78,83,92,112,120].…”

Section: Pd-l1 Immunohistochemical Expression In Different Specimen-types Of Prostatic Adenocarcinomamentioning

confidence: 99%

See 1 more Smart Citation

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Palicelli

Bonacini

Croci

et al. 2021

Cells

View full text Add to dashboard Cite

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.

show abstract

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)

Малярчиков

Шаповалов

Лукьянов

et al. 2021

Obŝaâ reanimatologiâ

View full text Add to dashboard Cite

Systemic inﬂammation is an integral pathophysiological component of many critical illnesses. The systemic inﬂammatory response is based on a cascade of interactions leading to hypercytokinemia and, as a consequence, multiple organ failure, which is one of the main causes of mortality in intensive care units.Aim of the study. To evaluate the activity of the negative regulation system of T-cell response by determining the plasma levels of PD-1, PD-L1 and PD-L2 molecules in pneumonia patients with inﬂuenza A (H1N1).Materials and methods. 85 patients with pneumonia and underlying inﬂuenza A (H1N1) were examined. Among them there were 30 patients with severe pneumonia, and 55 patients with non-severe pneumonia. Plasma levels of PD-1, PD-L1, PD-L2 molecules was determined by ﬂow cytoﬂuorometry method.Results. In patients with severe pneumonia and underlying inﬂuenza A (H1N1), the plasma level of PD-1 receptor increased 4.6-fold, while the concentration of its ligands PD-L1 and PD-L2 increased 10.6 and 2.2-fold, respectively.Conclusion. Signiﬁcant increase in levels of PD-1 and its ligands PD-L1 and PD-L2 in patients with pneumonia and underlying inﬂuenza A (H1N1) indicates the involvement of negative regulation system of T-cell response in the cascade of immunological reactions and is associated with the severe disease. Possible correction of immune reactions realized through PD-1/PD-L1/PD-L2 complex in critically ill patients is a promising research avenue.

show abstract

The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer

Cited by 8 publications

References 33 publications

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)

Contact Info

Product

Resources

About